Il-1 binding proteins
OwnerChung-ming Hsieh, Chengbin Wuinventors
Life of this patent
Estimating the term…
Abstract
The present invention encompasses IL-1α binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Antibodies of the invention have high affinity for IL-1α and neutralize IL-1α activity. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting IL-1α and for inhibiting IL-1α activity, e.g., in a human subject suffering from a disorder in which IL-1α activity is detrimental.
Claims12
1-47. (canceled)
A method for reducing human IL-1α activity in a human subject suffering from a disorder in which IL-1α activity is detrimental comprising administering to the human subject an antibody comprising a variable heavy chain domain comprising an amino acid sequence selected from the group consisting of SEQ ID NO:
- 37, SEQ ID NO:
- 38, SEQ ID NO:
- 39, SEQ ID NO:
- 40, SEQ ID NO:
- 48, SEQ ID NO:
- 50, SEQ ID NO:
- 52, and SEQ ID NO:
- 54;
- and a variable light chain domain comprising an amino acid sequence selected from the group consisting of SEQ ID NO:
- 41 SEQ ID NO:
- 42, SEQ ID NO:
- 43, SEQ ID NO:
- 44, SEQ ID NO:
- 45, SEQ ID NO:
- 46, SEQ ID NO:
- 47, SEQ ID NO:
- 49, SEQ ID NO:
- 51, SEQ ID NO:
- 53, and SEQ ID NO:
- 55;
- wherein the antibody is capable of specifically binding human IL-1α such that human IL-1α activity in the human subject is reduced.
A method for treating a subject for a disease or a disorder in which IL-1α activity is detrimental comprising administering to the subject an antibody comprising a variable heavy chain domain comprising an amino acid sequence selected from the group consisting ID NO:
- 40, SEQ ID NO:
- 48, SEQ ID NO:
- 50, SEQ ID NO:
- 52, and SEQ ID NO:
- 54;
- and a variable light chain domain comprising an amino acid sequence selected from the group consisting of SEQ ID NO:
- 41 SEQ ID NO:
- 42, SEQ ID NO:
- 43, SEQ ID NO:
- 44, SEQ ID NO:
- 45, SEQ ID NO:
- 46, SEQ ID NO:
- 47, SEQ ID NO:
- 49, SEQ ID NO:
- 51, SEQ ID NO:
- 53, and SEQ ID NO:
- 55;
- wherein the antibody is capable of specifically binding human IL-1α, such that treatment is achieved.
(canceled)
Dependencies are inferred from the claim text.